One known mediator in the development of both glomerulosclerosis and tubulointerstitial fibrosis is transforming growth factor- β1 (TGF-β1)[6]; however, because of its pleiotropic actions, TGF-β may not be an ideal therapeutic target. This evidence concerns the gene TGFB1 and glomerulosclerosis.